Kyverna Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Kyverna Therapeutics Inc 's ROA in the second quarter of 2026?
Kyverna Therapeutics Inc recorded a cumulative net loss of $-153 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -54.37%.

However, within the Healthcare sector 635 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4079, from total ROA ranking in the first quarter of 2026 at 4762.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	68.47 %	0.37 %	-1.71 %	-44.28 %	-35.44 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-153	-156	-161	-161	-159
Return On Assets (TTM)	-54.37 %	-64.79 %	-66.89 %	-66.41 %	-56.85 %
KYTX's Total Ranking	# 4079	# 4762	# 4180	# 4143	# 4091
Total Assets (TTM) in million	387	257	294	185	230
Seq. Total Assets Change	50.73 %	-12.53 %	59.07 %	-19.67 %	-10.2 %
Seq. Net Income Change	-	-	-	-	-

KYTX's 5 Years Annual ROA >> Back to KYTX Management Effectiveness >> Compare KYTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 90
Sector	# 636
Overall	# 4031

Return On Assets Statistics
High	Average	Low
-36.5 %	-57.08 %	-66.65 %
(Dec 31 2024)		(Dec 31 2025)

News about Kyverna Therapeutics Inc Return on Assets ROA

Kyverna Therapeutics Unveils KYV-101 A Potential Game-Changer in Multiple Sclerosis Treatment,

Promising Advances in Multiple Sclerosis Treatment: Kyverna Therapeutics Highlights KYV-101 at ECTRIMSKyverna Therapeutics is generating significant interest in the field of multiple sclerosis (MS) research with their recent report on KYV-101, an innovative CAR T-cell therapy currently undergoing investigator-initiated trials. The data, set to be presented at the upcoming European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference, showcases promising clinical outcomes that could mark a significant step forward in the treatment of this debilitating condition.The Phase 1 trials of KYV-101 demonstrate several noteworthy findings. One of the most compelling aspects of the data is the evidence of robust CAR T-cell penetration into the central nervous system (CNS). This is a crucial factor in the treatment of multiple sclerosis, as it suggests that the therapeutic approach may effectively target and intervene in the disease process directly within the CNS, where MS pathology manifests.

Financial Statements
Kyverna Therapeutics Inc 's Assets	$ 387 million	KYTX's Balance sheet
Kyverna Therapeutics Inc 's Income	$ -38 million	Quarterly KYTX's Income Statement
KYTX's Income by Division		See KYTX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	FY	FY	FY
Y / Y Total Assets Change	-1.71 %	-	-	-	-
Total Assets in million	294	299	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-161	-127	0	0	0
Annual Return On Assets	-54.9 %	-42.64 %	-	-	-

KYTX's 5 Years Annual ROA >> Back to KYTX Management Effectiveness >> Compare KYTX ROA to its Competitors

More Return On Assets Ratios
KYTX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
KYTX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for KYTX's Competitors
Subscribers only: Roa for Kyverna Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for KYTX's Customers

You may also want to know
KYTX's Roi	KYTX's Inventory Turnover Ratio	KYTX's Growth Rates	KYTX's Dividend Comparisons
	KYTX's Profitability Ratios	KYTX's Asset Turnover Ratio	KYTX's Dividend Growth
KYTX's Roe	KYTX's Valuation Ratios	KYTX's Financial Strength Ratios	KYTX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:43:07+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.